Humacyte (NASDAQ:HUMA) Hits New 12-Month High at $5.09

Humacyte, Inc. (NASDAQ:HUMAGet Free Report)’s stock price reached a new 52-week high on Monday . The company traded as high as $5.09 and last traded at $4.95, with a volume of 559791 shares traded. The stock had previously closed at $4.70.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on HUMA. Piper Sandler reaffirmed a “neutral” rating and issued a $4.00 target price on shares of Humacyte in a research report on Tuesday, March 26th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 target price on shares of Humacyte in a research report on Monday, April 1st. Finally, Benchmark reissued a “buy” rating and set a $15.00 price objective on shares of Humacyte in a research report on Monday.

Read Our Latest Stock Report on Humacyte

Humacyte Stock Up 16.4 %

The company’s 50-day moving average is $3.52 and its 200 day moving average is $3.16. The company has a market capitalization of $651.37 million, a PE ratio of -5.09 and a beta of 1.27. The company has a debt-to-equity ratio of 1.20, a quick ratio of 4.52 and a current ratio of 4.52.

Humacyte (NASDAQ:HUMAGet Free Report) last released its quarterly earnings results on Friday, March 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01. During the same period in the previous year, the company earned ($0.21) earnings per share. As a group, analysts anticipate that Humacyte, Inc. will post -0.9 EPS for the current year.

Institutional Investors Weigh In On Humacyte

A number of large investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Humacyte by 350.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock worth $34,000 after buying an additional 9,325 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Humacyte by 52.8% during the 4th quarter. SG Americas Securities LLC now owns 16,340 shares of the company’s stock worth $46,000 after acquiring an additional 5,645 shares during the last quarter. Powell Investment Advisors LLC grew its position in shares of Humacyte by 75.0% during the 4th quarter. Powell Investment Advisors LLC now owns 21,000 shares of the company’s stock valued at $60,000 after acquiring an additional 9,000 shares during the period. Private Advisor Group LLC increased its stake in shares of Humacyte by 126.1% in the 3rd quarter. Private Advisor Group LLC now owns 94,980 shares of the company’s stock worth $278,000 after purchasing an additional 52,980 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. bought a new position in Humacyte in the 4th quarter worth $28,000. 44.71% of the stock is currently owned by institutional investors.

About Humacyte

(Get Free Report)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

Featured Articles

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.